氟哌噻吨美利曲辛片对功能性胃肠病伴焦虑抑郁障碍患者的临床疗效分析

Clinical efficacy analysis of flupentixol and melitracen tablets in the treatment of functional gastrointestinal diseases with anxiety and depression disorder

目的探究氟哌噻吨美利曲辛片对功能性胃肠病伴焦虑抑郁障碍患者的治疗效果。方法90例功能性胃肠病伴焦虑抑郁障碍患者,采取抽签方式将患者分为研究组与对照组,各45例。对照组患者采用常规药物进行治疗,研究组患者在对照组基础上加用氟哌噻吨美利曲辛片进行治疗。比较两组患者治疗前后焦虑、抑郁状况及生存质量。结果治疗后,研究组患者汉密尔顿焦虑量表(HAMA)评分(8.91±2.17)分、汉密尔顿抑郁量表(HAMD)评分(8.76±3.47)分低于治疗前的(27.84±6.83)、(21.08±5.32)分,对照组患者HAMA评分(15.72±4.29)分、HAMD评分(17.63±2.25)分低于治疗前的(26.85±5.47)、(22.94±3.96)分,且研究组患者HAMA、HAMD评分均低于对照组,差异具有统计学意义(P<0.05)。治疗后,研究组患者生存质量测定量表简表(QOL-BREF)总分(76.8±4.8)分均高于治疗前的(47.8±3.9)分,对照组患者QOL-BREF总分(67.1±4.2)分均高于治疗前的(46.0±2.8)分,且研究组患者QOL-BREF总分高于对照组,差异具有统计学意义(P<0.05)。结论氟哌噻吨美利曲辛片对功能性胃肠病伴焦虑抑郁障碍患者有良好的治疗效果,能够缓解患者的焦虑、抑郁程度,提高患者的生活质量,值得临床推广应用。

Objective To investigate the therapeutic effect of flupentixol and melitracen tablets in the treatment of functional gastrointestinal diseases with anxiety and depression disorder.Methods A total of 90 patients with functional gastrointestinal diseases complicated with anxiety and depression disorder were divided by lottery method into research group and control group,with 45 cases in each group.The control group was treated with conventional medicine,and the research group was treated with flupentixol and melitracen tablets on the basis of the control group.The anxiety and depression status before and after treatment,and quality of life was compared between the two groups.Results After treatment,the Hamilton anxiety scale(HAMA)and Hamilton depression scale(HAMD)scores were(8.91±2.17)and(8.76±3.47)points in the research group,which was lower than(27.84±6.83)and(21.08±5.32)points before treatment;the HAMA score and HAMD score were(15.72±4.29)and(17.63±2.25)points respectively in the control group,which was lower than(26.85±5.47)and(22.94±3.96)points before treatment.The HAMA score and HAMD score in the research group was lower than those in the control group,and their difference was statistically significant(P<0.05).After treatment,the total score of quality of life brief(QOL-BREF)in the research group was(76.8±4.8)points,which was higher than(47.8±3.9)points before treatment;the total score of QOL-BREF inthe control group was(67.1±4.2)points,which was higher than(46.0±2.8)points before treatment.The total score of QOL-BREF in the research group was higher than that in the control group,and the difference was statistically significant(P<0.05).Conclusion Flupentixol and melitracen tablets shows good therapeutic effect for patients with functional gastrointestinal diseases complicated with anxiety and depression disorder,and it can alleviate the anxiety and depression of patients and improve their quality of life.It is worthy of clinical promotion and application.